drugset / Trial / NCT03691831

A Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03691831

Phase 3 Completed 502 enrolled Aclaris Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 Study of A-101 Topical Solution in Subjects with Common Warts

Timeline

Start
2018-09-13
Primary completion
2019-04-21
Completion
2019-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrogen Peroxide Small molecule 45 % Topical

Indications